Market capitalization | KRW3.91t |
Enterprise Value | KRW2.78t |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 13.83 |
P/S ratio (TTM) P/S ratio | 19.44 |
P/B ratio (TTM) P/B ratio | 2.23 |
Revenue growth (TTM) Revenue growth | -51.98% |
Revenue (TTM) Revenue | KRW201.30b |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
3 Analysts have issued a SK Bioscience forecast:
3 Analysts have issued a SK Bioscience forecast:
Sep '24 |
+/-
%
|
||
Revenue | 201,300 201,300 |
52%
52%
|
|
Gross Profit | 47,733 47,733 |
70%
70%
|
|
EBITDA | -86,362 -86,362 |
3,463%
3,463%
|
EBIT (Operating Income) EBIT | -123,068 -123,068 |
298%
298%
|
Net Profit | -43,274 -43,274 |
194%
194%
|
In millions KRW.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
SK bioscience Co., Ltd. engages in the development and distribution of bio and vaccine products. The company was founded on July 1, 2018 and is headquartered in Seongnam-si, South Korea.
Head office | South Korea |
CEO | Jae-Yong An |
Employees | 1,095 |
Founded | 2008 |
Website | www.skbioscience.co.kr |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.